Skip to content

Evidence

Multistage AI-Driven Workflow Improves General Radiologist Screening Mammography Performance to the Level of Fellowship-Trained Breast Imagers: Real-World Evidence in >500,000 Patients

RSNA: Podium Presentation
McCabe et al. 2025

 

Interpretive performance in screening mammograms (SMGs) varies widely. An AI-driven workflow was deployed at scale, and performance before and after implementation was compared between radiologists with and without fellowship training in breast or women’s imaging. The Multistage AI-Driven workflow significantly improved CDR and PPV1 for General radiologists to levels comparable with Fellowship-trained radiologists.

Large-Scale Deployment of a Multistage AI-Driven Workflow Increases Detection of Deadlier Breast Cancers

RSNA: Poster Presentation
Louis et al. 2025

 

This study assesses the cancer subtypes detected in a large-scale deployment of a multistage AI-driven workflow compared to the standard of care (SOC). Employing the multistage AI-driven workflow significantly improved clinical outcomes in terms of CDR in a cohort of over 2400 cancers, with the majority of cancers detected being clinically relevant and no corresponding increase in the proportion of DCIS, showing benefits for screening mammography.

206 Screening Benefits and Harms; A Review of False Positives and Negatives from the Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Targeted Lung Health Check (TLHC) Programme

BTOG: Poster Presentation
Palmer et al. 2025

 

Clinical outcomes from the SWAG TLHC programme were reviewed to better understand potential harms, including over-investigation, missed diagnoses and cancers developing between screening rounds. Of the scans reviewed, 4098/4198 (97.6%) were negative (confirmed true negatives) and 80/4198 (1.9%) were abnormal (confirmed true positives). One person was diagnosed with lung cancer 18 months after a reportedly normal TLC scan, giving a false negative rate of 0.02%.

AI Driven Safeguard Review Process Helps Detect Aggressive Breast Cancers

RSNA: Poster Presentation
Kim et al. 2024

 

An AI-driven safeguard review process was implemented prospectively, and its custom-built AI algorithm was used to flag the most suspicious screening DBT exams that had not been recalled by the initial interpreting radiologist. An expert breast imaging specialist performed a second, safeguard review of the 2,296 flagged exams. This resulted in the detection of 41 additional cancers, mostly invasive, 22.0% of which were deemed aggressive.

Disclaimers: DeepHealth Prostate is manufactured as Quantib Prostate by Quantib BV for DeepHealth Inc., DeepHealth Lung is manufactured as Veye Lung Nodules by Aidence BV for DeepHealth Inc., DeepHeath Lung Tracker is manufactured as Veye Clinic by Aidence BV for DeepHealth Inc. and DeepHealth Brain is manufactured as Quantib ND by Quantib BV for DeepHealth Inc. Not all products and functionalities are commercially available in all countries. For clearance and commercial availability in your geography of functionalities listed and compatibility with other systems, please contact us